PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24

PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24

SUMMARY

PharmEasy had an IRR of -41% in H1 FY24, as per data released by Prosus in its half yearly financial statements

PharmEasy was the second-biggest underperformer in Prosus’ global portfolio, with only Skillsoft reporting a worse IRR in H1 FY24

Edtech decacorn BYJU’S was another big underperformer for Prosus with an IRR of -24% in H1 FY24

Online pharmacy major pharmeasy was the biggest underperformer in the Indian portfolio of investment giant Prosus during the first half (H1) of the financial year 2023-24 (FY24).

According to Prosus’ financial statements, PharmEasy had an internal rate of return (IRR) of -41% in H1 FY24. In fact, the online pharmacy major was the second-biggest underperformer in Prosus’ global portfolio, with only Skillsoft reporting a worse IRR during the period under review.

A shareholder presentation shared by Prosus revealed that it held a 13% stake in PharmEasy at the end of September 2023. It also showed that the investment giant increased its stake in the online pharmacy unicorn during the period under review. 

However, Prosus marked down PharmEasy’s valuation amid the startup’s financial troubles. 

“Another is a write down in PharmEasy of about $118 Mn and that’s really driven by the need for PharmEasy to raise money to settle debt. We actually participated in that round which expresses our confidence in the business going forward,” a Prosus spokesperson said.

The startup recently raised INR 3,500 Cr (around $424 Mn) in a rights issue, in which Prosus also participated. The rights issue was oversubscribed, according to PharmEasy cofounder Dhaval Shah.

PharmEasy was looking to settle a portion of its debt from the proceeds of the rights issue.

Beyond PharmEasy, edtech decacorn BYJU’S was another big underperformer for Prosus, having reported an IRR of -24% during the six month period ended September 2023.

Meanwhile, Prosus earned profitable returns from other Indian firms in its portfolio, including Swiggy, Eruditus, PayU India, Meesho and Elastic Run. Prosus reported a profitable IRR of 7% for Swiggy, and 22% for Eruditus. It also earned 30% positive returns from PayU India, 32% from Meesho, and 31% from Elastic Run in H1 FY24.

Overall, the investment major’s operating loss rose to $415 Mn in H1 FY24 from $329 Mn in the year-ago quarter. The company attributed the surge in loss to an impairment loss recognised with respect to edtech investments.

Earlier today, Prosus also slashed BYJU’S valuation down to under $3 Bn, more than 85% lower than the edtech giant’s peak valuation of $22 Bn it commanded during its last funding round.

You have reached your limit of free stories
Become An Inc42 Plus Member

Become a Startup Insider in 2024 with Inc42 Plus. Join our exclusive community of 10,000+ founders, investors & operators and stay ahead in India’s startup & business economy.

2 YEAR PLAN
₹19999
₹7999
₹333/Month
Unlock 60% OFF
Cancel Anytime
1 YEAR PLAN
₹9999
₹4999
₹416/Month
Unlock 50% OFF
Cancel Anytime
Already A Member?
Discover Startups & Business Models

Unleash your potential by exploring unlimited articles, trackers, and playbooks. Identify the hottest startup deals, supercharge your innovation projects, and stay updated with expert curation.

PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24-Inc42 Media
How-To’s on Starting & Scaling Up

Empower yourself with comprehensive playbooks, expert analysis, and invaluable insights. Learn to validate ideas, acquire customers, secure funding, and navigate the journey to startup success.

PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24-Inc42 Media
Identify Trends & New Markets

Access 75+ in-depth reports on frontier industries. Gain exclusive market intelligence, understand market landscapes, and decode emerging trends to make informed decisions.

PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24-Inc42 Media
Track & Decode the Investment Landscape

Stay ahead with startup and funding trackers. Analyse investment strategies, profile successful investors, and keep track of upcoming funds, accelerators, and more.

PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24-Inc42 Media
PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24-Inc42 Media
You’re in Good company